$2.56
+0.05 (+1.99%)
Open$2.52
Previous Close$2.51
Day High$2.58
Day Low$2.49
52W High$3.22
52W Low$0.63
Volume—
Avg Volume606.9K
Market Cap161.26M
P/E Ratio18.81
EPS$0.05
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,124.2% upside
Current
$2.56
$2.56
Target
$31.34
$31.34
$21.51
$31.34 avg
$48.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 71.27M | 66.19M | 30.93M |
| Net Income | 9.15M | 7.64M | -5,880,957 |
| Profit Margin | 12.8% | 12.2% | -19.0% |
| EBITDA | 6.75M | 5.95M | -8,827,347 |
| Free Cash Flow | — | — | -6,633,459 |
| Rev Growth | +7.7% | +7.7% | +18.4% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |